There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IGF-I R


IGF-I R Molecule Information

Name:Insulin-like growth factor I receptor
Target Synonym:IGF-I receptor,IGF1R,Insulin Like Growth Factor 1 Receptor,Insulin-Like Growth Factor I Receptor,Soluble IGF1R Variant 1,Soluble IGF1R Variant 2,CD221 Antigen,CD221,IGFIR,JTK13,IGFR,Receptor, IGF Type 1,Insulin-Like Growth Factor 1 Receptor,MGC18216
Number of Launched Drugs:6
Number of Drugs in Clinical Trials:13
Lastest Research Phase:Approved

IGF-I R Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
IGR-H5229 Human Human IGF-I R / CD221 Protein, His Tag
IGR-C5225 Cynomolgus Cynomolgus IGF-I R / CD221 Protein, His Tag
IGR-R5224 Rat Rat IGF-I R / CD221 Protein, His Tag
IGR-M5223 Mouse Mouse IGF-I R / CD221 Protein, His Tag

IGF-I R Part of Bioactivity data

Cynomolgus IGF-I R, His TagCynomolgus IGF-I R, His Tag (Cat. No. IGR-C5225) ELISA bioactivity

Immobilized Cynomolgus IGF-I R, His Tag (Cat. No. IGR-C5225) at 5 μg/mL (100 μL/well) can bind Human IGF-I, Fc Tag (Cat. No. IG1-H4269) with a linear range of 0.02-0.3 μg/mL (QC tested).

Human IGF-I R, His TagHuman IGF-I R, His Tag (Cat. No. IGR-H5229) ELISA bioactivity

Immobilized Human IGF-I R, His Tag (Cat. No. IGR-H5229) at 5 μg/mL (100 μL/well) can bind Human IGF-I, Fc Tag (Cat. No. IG1-H4269) with a linear range of 0.04-0.313 μg/mL (QC tested).

IGF-I R Molecule Synonym Name


IGF-I R Molecule Background

The Insulin-like Growth Factor 1 Receptor (IGF1) is also known as CD221, JTK13. and is a transmembrane receptor that is activated by IGF-1 and by the related growth factor IGF-2. It belongs to the large class of tyrosine kinase receptors. This receptor mediates the effects of IGF-1, which is a polypeptide protein hormone similar in molecular structure to insulin. IGF1R is make up of two alpha subunits and two beta subunits ,the Both the ¦Á and ¦Â subunits are synthesized from a single mRNA precursor. The precursor is then glycosylated, proteolytically cleaved, and crosslinked by cysteine bonds to form a functional transmembrane ¦Á¦Â chain.The ¦Á chains are located extracellularly while the ¦Â subunit spans the membrane and are responsible for intracellular signal transduction upon ligand stimulation. IGF1R have a binding site for ATP, which is used to provide the phosphates for autophosphorylation. There is a 60% homology between IGF1R and the insulin receptor. In response to ligand binding, the ¦Á chains induce the tyrosine autophosphorylation of the ¦Â chains. This event triggers a cascade of intracellular signaling that, while somewhat cell type specific, often promotes cell survival and cell proliferation.

IGF-I R References

IGF-I R Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Mecasermin (Ipsen) IGF-1; FK-780; MKN-031 Approved Ipsen Increlex EU Laron Syndrome s:12:"Ipsen Pharma"; 2005-08-30 Failure to Thrive; Growth Disorders; Laron Syndrome Details
IGF-1 (Biogen/Pharmacia & Upjohn) Approved Biogen Inc, Pharmacia & Upjohn Igef Sweden Dwarfism s:4:"null"; 1994-01-01 Dwarfism Details
Mecasermin (Astellas/OrphanPacific) Approved Astellas Pharma Inc Somazon Japan Dwarfism; Diabetes Mellitus, Lipoatrophic; Growth hormone deficiency s:4:"null"; 1994-10-05 Diabetes Mellitus, Lipoatrophic; Dwarfism; Growth hormone deficiency Details
Teprotumumab R-1507; RG-1507; RO-4858696; HZN-001 Approved Genmab, F. Hoffmann-La Roche Ltd Tepezza United States Graves Ophthalmopathy s:28:"Horizon Therapeutics Ireland"; 2020-01-21 Graves Ophthalmopathy; Diabetic macular oedema; Sarcoma; Prostatic Neoplasms; Breast Neoplasms; Scleroderma, Diffuse Details
Insulin aspart NN-1218; INA-X14; Insulin X14 Approved Novo Nordisk A/S Novolog, NovoRapid, NovoLog FlexPen, NovoMix, Fiasp, 诺和锐, NovoRapid/NovoLog Japan Diabetes Mellitus s:16:"Novo Nordisk A/S"; 1999-09-07 Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetes Mellitus Details
Ceritinib LDK-378; NVP-LDK378; NVP-LDK378-NX Approved Novartis Pharma Ag 赞可达, Zykadia Mainland China Carcinoma, Non-Small-Cell Lung s:22:"Novartis Europharm Ltd"; 2014-04-29 Stomach Neoplasms; Glioblastoma; Adenocarcinoma of Lung; Pancreatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Hepatic Insufficiency; Lymphoma, Large-Cell, Anaplastic; Carcinoma, Squamous Cell; Granuloma, Plasma Cell; Esophageal adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma Details
Insulin degludec NN-1250; Insulin-454 Approved Novo Nordisk A/S 诺和达, Tresiba Mainland China Diabetes Mellitus, Type 2 s:16:"Novo Nordisk A/S"; 2012-09-28 Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetes Mellitus Details
Brigatinib AP-26113 Approved Takeda Pharmaceutical Co Ltd, Ariad Alunbrig Japan Carcinoma, Non-Small-Cell Lung s:6:"Takeda"; 2017-04-28 Solid tumours; Carcinoma; Myofibroma; Lymphoma, Large-Cell, Anaplastic; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details

IGF-I R Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
VPI-2690B VPI-2690B Phase 2 Clinical University Of North Carolina At Chapel Hill Diabetic Nephropathies Details
124I-CPD-1023-figitumumab 124I-CPD-1028; 125I-CPD-1028; CPD-1028-[124I]; CPD-1028-[125I]; FPX-1028 Phase 1 Clinical Fusion Pharma Neoplasms Details
BVS-857 BVS-857 Phase 2 Clinical Novartis Pharma Ag Insulin Resistance; Bulbo-Spinal Atrophy, X-Linked Details
IGF-1 receptor oligodeoxynucleotide-based immunotherapy (Thomas Jefferson University) Phase 1 Clinical Sidney Kimmel Cancer Center Glioma Details
Insulin-Like Growth Factor 1 (Wright State Physicians) Phase 1 Clinical Wright State Physicians Nasolabial fold wrinkles; Sunburn Details
Dalotuzumab h7C-10; MK-0646; F-50-035 Phase 2 Clinical Pierre Fabre Group Rectal Neoplasms; Pancreatic Neoplasms; Multiple Myeloma; Neuroendocrine Tumors; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Picropodophyllin PPP; AXL-1717; NSC-36407 Phase 2 Clinical Axelar Ab Astrocytoma; Carcinoma, Non-Small-Cell Lung Details
W-0101 (Pierre Fabre Medicament) W-0101 Phase 2 Clinical Pierre Fabre Group Neoplasms Details
BIIB-022 BIIB-022 Phase 1 Clinical Biogen Inc Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
IGV-001 IGV-001 Phase 2 Clinical Thomas Jefferson University Glioblastoma Details
Mecasermin Rinfabate SHP-607; HGT-ROP-001; rhIGF-I/rhIGFBP-3 Phase 2 Clinical Insmed Noonan Syndrome; Failure to Thrive; Cerebral Intraventricular Hemorrhage; Bronchopulmonary Dysplasia; Laron Syndrome; Retinopathy of Prematurity; Muscular Dystrophies Details
Conteltinib CT-707; SY-707 Phase 3 Clinical Shouyao Holding (Beijing) Co Ltd, Beijing Sailintai Medicine Technology Co Ltd Carcinoma, Non-Small-Cell Lung Details
Ganitumab AMG-479 Phase 3 Clinical Amgen Inc Sarcoma, Ewing; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Gastrointestinal Neoplasms; Lung Neoplasms; Lymphoma; Colorectal Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Intestinal Neoplasms; Sarcoma; Small Cell Lung Carcinoma; Colonic Neoplasms; Pancreatic Neoplasms; Rectal Neoplasms; Carcinoid Tumor; Solid tumours; Ovarian Neoplasms Details
CT102 CT-102 Phase 1 Clinical Institute Of Radiological Medicine, Chinese Academy Of Military Medical Sciences, Hangzhou Tianlong Pharmaceutical Co Ltd Carcinoma, Hepatocellular Details

This web search service is supported by Google Inc.